Why Alpha Cognition Inc.’s (ACOG) Stock Is Down 6.42%
As of Friday, August 21, Alpha Cognition Inc.’s ACOG share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Commentary & Analysis
Why Alpha Cognition Inc.’s (ACOG) Stock Is Down 6.56%
As of Monday, August 17, Alpha Cognition Inc.’s ACOG share price has dipped by 6.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Alpha Cognition Inc.’s (ACOG) Stock Is Up 7.42%
As of Friday, August 14, Alpha Cognition Inc.’s ACOG share price has surged by 7.42%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Alpha Cognition Inc.’s (ACOG) Stock Is Down 10.08%
As of Friday, July 31, Alpha Cognition Inc.’s ACOG share price has dipped by 10.08%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Alpha Cognition Inc.’s (ACOG) Stock Is Up 5.82%
As of Monday, July 27, Alpha Cognition Inc.’s ACOG share price has surged by 5.82%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACOG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $212.3 | $292.6 | 27% |
|
| Shares Out (Mil) | 21.8 | 54.4 | 31% |
|
| Institutional Ownership | 63.7% | 93.2% | 40% |
|
| Float (Mil) | 11.6 | 40.2 | 21% |
|
| Beta | 2.23 | 0.94 | 95% |
|
| Avg Daily Volume (000s) | 192 | 544 | 43% |
|
| Price Change (52-week) |
22.0% | 59.7% | 62% |
|
| Growth | ACOG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (29.0%) | (10.1%) | 14% |
|
| EPS (5yr) | 18.9% | 16.0% | 66 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 31.7% | (15.6%) | 87% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 1 | 5 | |
| Current EPS | ($0.332) | ($1.260) | ($0.620) | |
| Month Ago EPS | ($0.348) | ($1.290) | ($0.630) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.337) | ($1.303) | ($0.437) | |
| Year/Year Chg | (17.8%) | 6.9% | (152.6%) | |
| Financials | ACOG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 23% |
|
| EPS (TTM) | ($1.022) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $2 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $166 | $164 | 25% |
|
| Valuation | ACOG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.01 | 2.83 | 72% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ACOG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 90.4% | 64.2% | 94% |
|
| Net Margin | (137.7%) | (75.9%) | 6% |
|
| ROA | (38.3%) | (47.5%) | 14% |
|
| ROE | (49.5%) | (55.0%) | 15% |
|
| Liabilities to Assets | 17.9% | 29.6% | 12% |
|
| F-Score | 1 | 3 | 1% |
|
Alpha Cognition Inc. did not pass any screens on 8/21/2026.
